# TEMPCHAIN

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tempchain

- Headquarters: Incheon, South Korea
- Website: www.tempchain.co.kr/
- Latest round: Series A (Jun 23, 2026)
- Investors on record: 5

## About

Based in South Korea, TEMPCHAIN is a company that specializes in creating advanced cold chain solutions to ensure the safe transport of sensitive biopharmaceutical products, particularly under stringent temperature controls. TEMPCHAIN was founded in 2022 and operates from Incheon, South Korea. The company focuses on the manufacturing of advanced cold chain passive transportation containers. In June 2026, TEMPCHAIN raised an undisclosed amount in series A funding from NVC Partners, Midas Donga Investment, Capstone Partners, Korea Credit Guarantee Fund, and Synergy IB Investment.

Temchain Co., Ltd. specializes in the manufacturing of advanced cold chain passive transportation containers, primarily aimed at preserving the integrity of biopharmaceuticals during transit. Their flagship product line, BioKeeper, includes several models designed to maintain critical temperatures for sensitive biological materials such as mRNA vaccines, which require storage at temperatures as low as -70°C and -20°C, as well as biomedicine that must be kept between 2°C and 8°C. The company's products address the increasing challenges of temperature control in biopharmaceutical transportation, which has seen a significant percentage of biological products compromised annually due to failures in cold chain systems. Temchain's customer base includes pharmaceutical companies, vaccine manufacturers, and healthcare providers across various regions, including North America, Europe, and Asia, where stringent regulations demand reliable temperature management for biological products.Temchain Co., Ltd. generates revenue through the sale and distribution of their cold chain solutions, particularly focusing on B2B transactions with key players in the pharmaceutical and healthcare sectors. The company engages in direct sales to clients, including pharmaceutical manufacturers and logistics providers, who require high-performance temperature-controlled transport solutions. Revenue streams include one-time purchases of their BioKeeper products, as well as potential service agreements for maintenance and support. The company’s commitment to advanced technology and superior quality positions them favorably within the competitive landscape of cold chain logistics. The company will use the June 2026 funds to develop new products for maritime biopharmaceutical transportation.

## Funding rounds

- Series A, Jun 23, 2026 — Capstone Partners, Midas Donga Investment, Korea Credit Guarantee Fund, Synergy IB Investment, NVC Partners

## Investors

- Capstone Partners (https://capitalatlas.ai/funds/capstone-partners) — Series A
- Midas Donga Investment (https://capitalatlas.ai/funds/midas-donga-investment) — Series A
- Korea Credit Guarantee Fund — Series A
- Synergy IB Investment (https://capitalatlas.ai/funds/synergy-ib-investment) — Series A
- NVC Partners (https://capitalatlas.ai/funds/nvc-partners) — Series A